Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Evaluation of use of ceftaroline and ceftobiprole : patients
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftaroline: dosage
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftaroline : PJI/BJI
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftobiprole: dosage
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftobiprole: PJI/BJI
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of failure under ceftaroline
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of failure under ceftobiprole
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)